3:13 PM
Jan 27, 2017
 |  BC Extra  |  Financial News

ICER finds Lemtrada most cost-effective in MS

In an evidence report evaluating disease-modifying therapies for multiple sclerosis, the Institute for Clinical and Economic Review said Lemtrada alemtuzumab from Sanofi (Euronext:SAN; NYSE:SNY) "consistently demonstrated improved health outcomes and good value" at a lower cost than other treatments.

ICER compared the effectiveness and value of 15 therapies, including several interferons; Copaxone glatiramer acetate and its generic competitor Glatopa; Tecfidera dimethyl fumarate; Gilenya fingolimod; and Zinbryta daclizumab in a network...

Read the full 367 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$50 USD
More Info >